CalcMyPeptide
Weight ManagementAlso known as: LY3305677, IBI362

Mazdutide

Mazdutide represents the bleeding edge of the "twincretin" revolution. Developed in China, it is an outrageously potent dual GLP-1 and Glucagon receptor agonist that has smashed Phase 3 clinical benchmarks for human obesity. By combining sheer appetite destruction with massive, active thermogenic fat-burning, it achieves staggering weight loss metrics (approaching 15-18%) that directly rival, and potentially outpace, Tirzepatide.

Reviewed by CalcMyPeptide Editorial Team
Last updated: April 2026Evidence: Emerging1 peer-reviewed citation

Quick Stats

Half-Life~6-7 days (once weekly)
Dose Range3-9 mg/week
Frequency1× every 2 weeks
Vial Sizes3 mg, 6 mg, 9 mg
Bioavailability~85% (SC estimated)
Year Developed2021

Scientific Data

Molecular Formula
Long-acting GLP-1/glucagon dual peptide
Molecular Weight
~4800–5000 Da
Developer
Innovent Biologics (China)

Mechanism of Action

Mazdutide (IBI362) is a dual GLP-1/glucagon receptor agonist (GCGr/GLP-1R) developed by Innovent Biologics. It combines GLP-1 agonism (appetite suppression, insulin secretion) with glucagon receptor agonism (increased hepatic fatty acid oxidation and energy expenditure) — the same glucagon-adding mechanism that makes retatrutide so potent. Phase 3 GLORY trials reported up to 18.6% body weight reduction at 9 mg over 48 weeks in Chinese patients with obesity.

Source: PMID: 37578886

Dosing Protocol

Typical Dose3-9 mg/week
Frequency1× every 2 weeks
Half-Life~6-7 days
Common Vial Sizes3 mg, 6 mg, 9 mg

Dosing Protocols

Escalation

Dose
3 mg → 6 mg → 9 mg
Frequency
Once weekly (SC)
Note: Phase 3 GLORY protocol: escalate every 4 weeks. 9 mg target dose.

Administration

Route
Subcutaneous injection
Timing
Once weekly, same day. Meal timing not required.
Fasting Required?
No — food timing not critical

Expected Timeline

Month 1-3
Rapid weight loss onset — glucagon dual-agonism drives higher early energy expenditure vs GLP-1 alone.
Month 6-12
Up to 18.6% body weight reduction at highest dose in Phase 3 GLORY trials.

Who Is It For?

Obesity / Weight Management

High

Phase 3: 18.6% BWL at 9 mg over 48 weeks. Approved in China 2024; global regulatory submission pending.

Metabolic Liver Disease (MASH)

Emerging

Glucagon receptor agonism reduces hepatic fat accumulation — early trial signals.

Reconstitution Example

Vial
6 mg
Water
2 mL
Concentration
3 mg/mL
Per Unit (100u syringe)
30 mcg
Dose of 3000 mcg = 100 units on a 100-unit insulin syringe
🧮 Calculate Your Exact Mazdutide Dose →

Safety & Considerations

Approved in China (2024) for obesity. Not FDA-approved. GI side effects consistent with GLP-1 class. Investigation ongoing in global Phase 3 trials.

Regulatory & Legal Status

FDA Status (US)
Research Only
WADA Status (2026)
Not Listed

Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Dosing Quick Reference

Mazdutide— Dosing Guide
Dose Range
3-9 mg/week
Half-Life
~6-7 days
Frequency
1× every 2 weeks
Route
Subcutaneous
3 mg vial6 mg vial9 mg vial
💧 2 mL BAC water📐 3 mg/mL concentration💉 30 mcg/unit (100u syringe)
Weight Managementcalcmypeptide.com

Frequently Asked Questions

Is mazdutide approved in the US?▼
Not yet. Mazdutide was approved in China in 2024 for obesity. Global (including US) Phase 3 trials are ongoing.
How does mazdutide compare to tirzepatide?▼
Both target GLP-1 plus a second receptor. Tirzepatide adds GIP; mazdutide adds glucagon. Mazdutide's glucagon component increases energy expenditure more aggressively. Tirzepatide has more mature global trial data.

References

  1. Ji L et al. “"Mazdutide (IBI362) in Chinese adults with obesity (GLORY-1)".” The Lancet Diabetes & Endocrinology (2024).

📚 Related Articles

GLP-1 Dose Escalation Guide: Semaglutide, Tirzepatide & Retatrutide
14 min read • Pillar Guide

Looking for a trusted source? See our recommended suppliers →

Independently tested · COA-verified · Save 10% with our exclusive code

← Back to Peptide Library